Recormon - pharmacological drug stimulating hematopoiesis (blood), used to treat anemia.
Structure and Composition
According to the instructions Recormon is available as a lyophilisate for solution for intravenous or subcutaneous administration. The active ingredient - epoetin beta. Produced the drug in the syringe tubes (with a ready solution) or a two-part cartridges (with lyophilisate and solvent).
One syringe-tube with the solution for subcutaneous or intravenous administration (0, 3 ml) containing 1,000 IU or 2,000 IU eopoetina beta.
A syringe-tube with a solution for subcutaneous and intravenous administration (0, 6 ml) contains 10,000 IU, or 20000ME 30000ME eopoetina beta.
Also included in the NeoRecormon auxiliary ingredients: sodium chloride, urea, disodium phosphate, sodium dihydrogen phosphate, calcium chloride, polysorbate, L-leucine, glycine, L-isoleucine, L-glutamic acid, L-threonine, L-phenylalanine, water. The solution is clear, colorless appearance of NeoRecormon.
Cartridge lyophilisate for solution for subcutaneous administration consists of two sections - the active substance and solvent. The first section contains eopoetin beta (or 20000ME 10000) and auxiliary components. The second section contains solvent (benzyl alcohol, benzalkonium chloride, water). Outwardly, lyophilisate NeoRecormon is a homogeneous white powder. In preparing the solution turns clear, colorless liquid.
Pharmacological action NeoRecormon
According to the instructions Recormon promotes transformation erythrocyte precursors into mature cells. The drug is the product of genetic engineering, its composition it is similar to human erythropoietin. Recormon not affect leykopoez and has no cytotoxic effect on the bone marrow and skin cells.
According to the instructions Recormon is shown under the following conditions:
- anemia in patients with chronic kidney disease (including if they are on dialysis);
- anemia in patients with neoplasms (including, if they are receiving chemotherapy);
- prevention of anemia in infants born prematurely weighing 75-1500g (up to 34 weeks of pregnancy);
- to increase the volume of blood that is intended for subsequent autotransfusion.
Hypersensitivity to the ingredients of the drug are not correctable hypertension, myocardial infarction or stroke within 1 month, unstable angina pectoris, increased risk of deep vein thrombosis (venous thromboembolism). The use of cartridges is contraindicated for children under 3 years.
According to the instructions Recormon should be used with caution in epilepsy, chronic liver failure, thrombocytosis, refractory anemia with the presence blasttransformirovannyh cells. Also with care active drug should be used to increase the volume of donor blood if the patient's body weight less than 50 kg.
Use during pregnancy and lactation
According to the instructions Recormon not show teratogenic effects in animal experiments. During pregnancy and lactation the drug should be used with extreme caution, because there is not enough clinical experience on the use of NeoRecormon in this period. This drug passes into breast milk. At the time of application of NeoRecormon is better to stop breast-feeding.
Dosage and administration of NeoRecormon
1. Treatment of anemia in patients with chronic kidney disease.
According to the instructions Recormon is administered subcutaneously or intravenously. Patients who are on hemodialysis, the drug is administered through the arteriovenous shunt at the end of the session. Patients who do not receive hemodialysis is recommended to enter Recormon subcutaneously. The goal of treatment is to increase hemoglobin levels to 100-120 g / l. Treatment with this drug is carried out in two phases - phase correction and maintenance treatment phase.
Phase correction: sc - initial dose of 20 IU / kg three times per 7 days. If necessary, the dose may be increased NeoRecormon every 4 weeks to 20 IU / kg. Intravenous - initial dose of 40 IU / kg three times per 7 days. If necessary, after 4 weeks, the dose can be increased up to 80 IU / kg three times per 7 days.
Regardless of the route of administration, the maximum dose of NeoRecormon should not exceed 720 IU / kg in 7 days.
Step maintenance therapy: to maintain hemoglobin index first dose should be reduced by 2 times from the start. Then, the maintenance dose is adjusted individually. Generally, treatment is carried out for a long time NeoRecormon.
2. Treatment of anemia in patients with tumors receiving chemotherapy.
Recormon administered subcutaneously, initial dose of 30,000 IU per week (450 IU / kg every 7 days). The preparation can be used 1 time per week or divided intake of 3 (or 7) days. NeoRecormon treatment must continue for another 1 month after the end of chemotherapy. The maximum weekly dose should not exceed 60,000 IU.
After achieving the target hemoglobin NeoRecormon dose should be reduced by 25-50%. If the hemoglobin after 8 weeks of treatment did not increase, the use of the drug should be discontinued, as the response to therapy is unlikely.
3. In order to prepare patients for blood donation for subsequent autologous transfusion.
Recormon injected intravenously (during 2 minutes) two times a week for a month. If the hematocrit (33%) makes it possible to take blood from a patient, the drug must be entered at the end of the procedure. During treatment Recormon hematocrit should not be higher than 48%. The dose of the drug is determined by the doctor individually.
4. To prevent anemia in premature infants.
Recormon injected subcutaneously 250 IU / kg 3 times per 7 days. Optimally to begin treatment with this drug 3 days of life, treatment for 6 weeks.
Recormon may rarely cause allergic reactions (skin rash, urticaria, pruritus, angioedema).
Cardio - vascular system may increase blood pressure, the occurrence of hypertensive crisis, thromboembolic complications (cancer patients).
From the nervous system marked the emergence of headaches, migraines.
Hematopoietic system Recormon could cause an increase in the number of platelets (especially after the intravenous route of administration). In rare cases, it noted the appearance of thrombosis of shunts.
From laboratory indicators active drug can cause a decrease in plasma concentrations of ferritin. Patients with renal insufficiency may occur hyperphosphatemia, hyperkalemia (transient).
Premature babies during treatment with NeoRecormon may decrease the concentration of ferritin in the blood plasma and a moderate increase in the number of platelets.
Chance of excessive response to treatment with this drug as an expression of erythropoiesis with life-threatening complications from cardio - vascular system. If a patient during therapy with NeoRecormon there is a high rate of hemoglobin, the need to interrupt treatment with this drug.
Interaction with other drugs
Currently, no evidence of the interaction of NeoRecormon with other drugs.
NeoRecormon analogues are the following drugs: epostim, epoetin, Vero epoetin, erythropoietin eopoetin beta Eritrea. Before replacing analogue NeoRecormon should consult a doctor.